NEXTGENPCR: 30 cycli, 3 temperatures, less than 2 minutes

Category

PRESSRELEASES

Leading diagnostics laboratory in the Caribbean selects NextGenPCR for SARS-CoV-2 testing

Clinical implementation of ultra-fast molecular testing improves time to result and laboratory throughput

 

Goes, Netherlands, March 31, 2021 — Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba’s Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing. With a single NextGenPCR system capable of producing over 1,000 results per day, Laboratorio di Servicio has ensured they have capacity beyond their current 300 test results per day.

 

“Last January, our lab Laboratorio di Servicio implemented the MBS’ NextGenPCR solution for CoV2 screening, on Aruba.” says Director of Clinical Chemistry at LdS, Robert Wever. “We found this ultra-fast PCR technology easy to use, sensitive, specific and overall, really ultra-fast, both in throughput as well as time to result.”

 

MBS has advanced the readout methodology first described last year in collaboration with the University of Bielefeld, to also be compatible with multi-color PCR assays that can monitor additional viral targets and process controls present in clinical diagnostic assays. Labs using ultra-fast RT-PCR in combination with proven SARS-CoV-2 tests and direct from sample RT-PCR has resulted in more than doubling their testing capacity.

 

“Throughout, labs have wanted to deliver more by increasing the efficiency of their workflow” says MBS CEO and founder, Gert de Vos. “So, Laboratorio di Servicio is just one example of how NextGenPCR has delivered higher throughput by reducing time spent on RT-PCR.”

 

Find out more at www.nextgenpcr.com

 

About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a life sciences solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.

 

About Laboratorio di Servicio N.V.

Laboratorio di Servicio N.V (LdS), formerly Service Lab Xpert, started delivering laboratory services to Aruba in August 2012. The focus of LdS is primary care, services to medical specialists, institutions, veterinary practices and private companies. LdS offers different clinical tests for allergy, diabetes, anemia, cancer, drug abuse, thyroid, pregnancy, the digestive system and more.

 

All referenced product names, and other marks, are trademarks of their respective owners.
© 2021 Molecular Biology Systems, B.V. All rights reserved.

 

 

Media contact:

Brian McNally, PhD
Molecular Biology Systems B.V.
Brian.mcnally@mbspcr.com

+1 301.366.1083

Ultrafast RT-PCR for COVID-19 by Molecular Biology Systems draws Dutch government support

Publication demonstrates updated NEXTGENPCR accelerates detection of SARS-CoV-2 RNA from clinical samples

 

Goes, Netherlands, April 2, 2020 – Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced a publication detailing the use of its revolutionary NEXTGENPCR endpoint thermocycler to test for SARS-CoV-2 with a one-step reverse transcription polymerase chain reaction (RT-PCR) in 16 minutes. The article, titled ” Ultra-fast one-step RT-PCR protocol for the detection of SARS-CoV-2,” has been submitted as a preprint is available here: https://www.medrxiv.org/content/10.1101/2020.06.25.20137398v1

 

“We immediately started with a COVID-19 diagnostic project, since we already got a NEXTGENPCR thermocycler for sepsis diagnostics. Using this technology, we demonstrated with clinical RNA isolates, the ability to dramatically increase SARS-CoV-2 testing throughput without a loss in sensitivity.” says Prof. Dr. Christian Kaltschmidt, Cell Biology of the University of Bielefeld, the senior author of the publication.

 

MBS has developed and released two software packages that result in a streamlined workflow from isolated nucleic acid sample to result. First, the machine’s operating system has been updated with two enabling features, onboard reverse transcription and 2-step PCR. These features decrease the number of handling steps, and plate shuttling time which together result in an improved, shorter protocol. The second software package automates the measurement and analysis of endpoint fluorescence, allowing users to automate calls based on predetermined thresholds.

 

“After accelerating the CDC assay, we received a lot of positive feedback.” says MBS CEO and founder, Gert de Vos. “We added software, tested more WHO-recommended protocols and have collaborated with labs to deliver a demonstration of ultrafast RT-PCR for SARS-CoV-2.”

 

To support companies responding to COVID-19, the Dutch government has awarded funds to MBS. Rosco Efraïm, Project Manager Impuls Zeeland, stated “MBS demonstrated a clear contribution to the advancement of SARS-CoV-2 testing both locally and globally, so the government awarded these funds to ensure this innovative company executes its mission.”

 

With a single NEXTGENPCR system delivering over 570 test results per hour, MBS is now collaborating with government and private testing laboratories in the USA, Europe, the Middle East and Africa to implement this method.

 

Find out more at www.nextgenpcr.com

 

About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.

 

All referenced product names, and other marks, are trademarks of their respective owners.

© 2020 Molecular Biology Systems, B.V. All rights reserved.

 

 

Media contact:

Brian McNally, PhD
Molecular Biology Systems B.V.
Brian.mcnally@mbspcr.com

+1 301.366.1083

Molecular Biology Systems accelerates CDC-designed assay while alleviating consumable demand

 

Goes, Netherlands, March 31, 2020 — Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has developed a method using its revolutionary NEXTGENPCR endpoint thermocycler and consumables that decreases PCR amplification time for SARS-CoV-2 to eight minutes. Combined with smaller reaction volumes, increased samples per run, and standard, affordable laboratory equipment, a qualitative protocol was generated that could readily detect SARS-CoV-2 control DNA, with equivalent sensitivity. A single unit, the size of a shoebox, could perform a hundred and eighty (180) amplification runs a day, an almost ten-fold increase over the current US Centers for Disease Control (CDC) recommended instrumentation. Detection of amplified product can be done with widely-available blue light gel document systems.

 

“We sought to decrease what we identified as the longest step in the current testing scheme, amplification.” says MBS CEO and founder, Gert de Vos. “We started with the CDC assay because it is well characterized and has been readily available.”

 

Since the NEXTGENPCR accepts both 96 and 384-well reaction plates, MBS tested both versions to increase throughput. By utilizing 384-well plates, the machine successfully processed four times as many samples without a loss in performance. The 384-well reaction chambers only require twenty-five percent of the reaction volume which would lower the supply burden placed on laboratories following the current CDC protocol.

 

NEXTGENPCR machines launched about two years ago and are available globally. Gert de Vos stated “This protocol produces a simple yes/no answer — so a single machine, is capable of running 24/7, with 8-minute runs may provide a scalable screening solution analyzing 22,860 samples per day.”

 

MBS is now collaborating with testing laboratories in the USA and the Netherlands to transfer and validate the method.

 

Find out more at www.nextgenpcr.com

 

About Molecular Biology Systems

Molecular Biology Systems, B.V., founded in 2015, is a molecular biology solutions company based in Netherlands. Their NEXTGENPCR thermocycler uses patented heating and cooling technology to reduce PCR amplification cycles from hours to minutes. These technological advances are intended to support laboratorians across the life sciences market reduce costs and accelerate results.

 

All referenced product names, and other marks, are trademarks of their respective owners.

© 2020 Molecular Biology Systems, B.V. All rights reserved.

 

 

 

 

Molecular Biology Systems and Velocidy Bio sign distribution agreement.

NEXTGENPCR, the ultrafast PCR system, is now available in the United States and Canada.

Goes, Netherlands, Feb. 19, 2020

Molecular Biology Systems (MBS), the developer of NEXTGENPCR, is pleased to announce their newest distributor, Velocidy Bio. Velocidy Bio becomes the exclusive distributor of NEXTGENPCR instruments, accessories and consumables in the United States and Canada. NEXTGENPCR is an innovative thermal cycler that can reduce cycling programs to less than two minutes, by both eliminating ramp times as well as reducing dwell times.

“NEXTGENPCR is an innovative solution that accelerates nucleic acid amplification, so we identify special commercial partners that will support users as they adopt our system.” states Gert de Vos, Founder and CEO of Molecular Biology Systems. “We look forward to working with Velocidy Bio, an innovative distributor focused on improving the laboratory experience by accelerating protocols.”

The NEXTGENPCR’s design does not disrupt current laboratory workflows, instead it accelerates the cycling protocol. Therefore, the NEXTGENPCR system has been widely adopted across laboratory segments including public and private research and testing labs in academia, government, biotech and pharmaceutical. Since launching two years ago, MBS has increasing the rate of NEXTGENPCR placements.

The NEXTENPCR instrument, accessories, and consumables are now available in the United States and Canada for purchase through Velocidy Bio at www.velocidybio.com. For other countries, please see Molecular Biology Systems’ commercial partners at www.nextgenpcr.com/buy-nextgen-pcr/

About Molecular Biology Systems

Molecular Biology Systems B.V. is a Netherlands company that developed and commercialized NEXTGENPCR, a universal ultrafast PCR system. The NEXTENPCR instrument uses an innovative temperature control method during cycling, which eliminates ramp time. Molecular Biology Systems offers their NEXTGENPCR instrument, accessories and consumables around the world, to laboratories in life science research, pharmaceutical and biotechnology companies, forensics, veterinary testing and food safety. Further information can be found at www.nextgenpcr.com.

About Velocidy Bio, Inc.

Velocidy Bio is focused on delivering solutions that decrease time-to-results for biological laboratories. Working together with innovative organizations, Velocidy Bio offers solutions globally that reduce protocols from hours to minutes. These accelerated protocols enable scientists to increase their productivity and reduce stress associated with delays in generating results.  Initially, Velocidy Bio is focused on reducing the time required to extract, amplify and analyze nucleic acids. Further information can be found at www.velocidybio.com.

 

See 2 minute PCR at the ASHG

Molecular Biology Systems will be exhibiting at this year’s American Society of Human Genetics Conference from October 15-19, 2019 in Houston, USA. MBS is looking forward to meeting those attending. To learn more about NextGenPCR, stop by Booth 107 any time during the exhibit.


MBS introduces NextGenPCR. Using SBS-plate format a 100bp fragment can be amplified in 2 minutes (30 cycles, 3 temperatures). Longer fragments take slightly longer, but will still be amplified in minutes rather than hours. This versatile system lets you run 96-well plates and 384-well plates without changing blocks. Volumes range from 3 to 50 microliters. The technology has proven to work over a wide range of application.



For more information about American Society of Human Genetics Conference 2019, visit their website.

We hope to see you in Houston, USA!

 

JULY
Webinar on NextGenPCR by Gert de Vos (founder & CEO of MBS) still available for viewing

Until now PCR instruments have relied on Peltier elements to heat and cool an aluminum or silver block, accommodating 96 or 384 polypropylene tubes, holding PCR-mixes. Using this technology PCR times, for 30 cycle, 3-temperature reactions, are usually between 50 and 150 minutes. Now, NEXTGENPCR is redefining fast. The thermocycler introduces a new way to heat and cool the samples instantly, with virtually no ramp rates, losing no time getting the samples to the desired temperature.

The user can go from melting to annealing in less than 0.1 second. For a 100 base pair fragment, total reaction time is as low as 2 minutes, with 700 base pairs being amplified in 10 minutes. Adding NEXTGENPCR into workflows results in higher sample throughput. Using optimized applications, more than 10 full plate experiments per hour become possible. Operated at capacity this would mean 80, 384-well plates per day, resulting in more than 30,000 datapoints per day; far beyond the capabilities of common thermocyclers.

Gert held a live presentation about the NextGenPCR on May 31st. During the presentation, Gert has focused on the technology behind NEXTGENPCR. Special attention has paid to publications detailing 2 minute PCR data and how NEXTGENPCR amplified all 29 fragments of the BRCA1 gene in less than 10 minutes for subsequent Sanger sequencing.
The video is still possible to view. To watch the video, please click on the link below and register.

 

REGISTER AND VIEW NOW

The webinar is sponsored by our distributor in the US and Canada: Canon Biomedical

 

 

 

Partnership rapidly provides NEXTGENPCR to US and Canadian customers

Amsterdam, April 23rd 2018:

Dutch biotechnology company Molecular Biology Systems (MBS) today announced it will launch its revolutionary NEXTGENPCR thermal cycler in the US and Canada through Canon BioMedical, Inc., a wholly owned subsidiary of Canon U.S.A., Inc. focused on empowering the biomedical research and healthcare communities by developing, manufacturing, and marketing innovative technologies and solutions.

According to the latest surveys, the global life sciences instrumentation market continues to grow at a CAGR of 8.2% and is predicted to be worth $85.1 billion by 2022. The US and Canada account for the largest share, fueled by a rapid adoption rate of novel technologies, the large number of life science research studies conducted in the region, and increased funding for life science research activities.

Read the whole article:  MBS Inks Deal with Canon BioMedical

Superfast cycler stuns genomics community with sub-2 minute protocols

Amsterdam, July, 2017: Dutch biotechnology company Molecular Biology Systems(MBS) today reported major interest for its revolutionary NEXTGENPCR thermal cycler following the appearance of the first production models at the recent ESGH and LABVOLUTION meetings.

Described as the first real advance in thermal cycling for 15 years, the NEXTGENPCR dramatically slashes current time-consuming DNA amplification from hours to minutes.

Read the whole article: MBS-Post ESHG_LABVOLUTION Ver 1.5.09